Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Golimumab (Simponi; Centocor), the first once-monthly, self-injectable TNF-specific mAb, was recently launched for RA, psoriatic arthritis and ankylosing spondylitis. Golimumab has the potential ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial.

Simponi and Simponi Aria (golimumab) are prescribed to treat a variety of inflammatory conditions. Kroger is cutting about 200 employees across three office sites, and Albertsons is laying off ...

Simponi and Simponi Aria, also known by their generic name, golimumab, which are approved to treat a variety of inflammatory conditions. This marks the first U.S. BLA filing for a biosimilar to ...

About BAT2506 (golimumab) BAT2506 is a proposed biosimilar to Simponi® which is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule.

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference product Simponi ... it is the first golimumab biosimilar ...

Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha). Originator product Simponi ® is approved in the U.S. for moderate to severe ...

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application to the U.S. FDA to add an additional indication for Simponi (golimumab) to include chuldren two years and ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...

infusion, 3 mg/kg at 0, 2 and 6 weeks followed by maintenance every 4–8 weeks Golimumab Simponi® Human monoclonal antibody sc. injection, 50 mg every month Certolizumab Cimzia® Human ...